CD19/CD22 dual-specificity CAR-T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19/CD22 dual-specificity CAR-T cell therapy, covering 2018-03-20 to 2018-03-20. Get the full timeline:
Most recent: Clinical Trial Update: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma [Phase 1, Phase 2]